You are here

Development of Small Molecule Therapeutics for Emerging Viral Agents

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-20-P-0069
Agency Tracking Number: C192-006-0028
Amount: $167,442.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD192-006
Solicitation Number: 19.2
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-02-03
Award End Date (Contract End Date): 2021-01-03
Small Business Information
11189 Sorrrento Valley Rd, Ste 104
San Diego, CA 92121
United States
DUNS: 962535782
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Ken Mccormack
 (858) 766-0495
Business Contact
 Ken McCormack
Phone: (858) 766-0495
Research Institution

Ebolavirus species including Zaire (EBOV), Sudan (SUDV) and Bundibugyo (BDBV) are responsible for severe hemorrhagic fever outbreaks with high case fatalities in Africa. Weaponized pathogens present an additional threat to the health protection of the warfighter and first-generation prophylactic and therapeutic medical countermeasures (MCMs) may prove inadequate in biodefense settings. Ebolaviruses present both potential public health and bioweapons threats and the development of second-generation therapeutics targeting novel mechanisms for antiviral activity may help to provide auxiliary means of protection. We utilized a vesicular stomatitis virus (VSV) based pseudotyped virus platform to identify novel chemical series of Ebola virus cell entry inhibitors and through SAR expansion have identified compounds with submicromolar broad-spectrum ebolavirus antiviral activity. Lead compounds exhibit favorable in vitro and in vivo drug-like properties promoting them as attractive next generation Ebola inhibitors for the development of dual use therapeutics.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government